This report on global autoimmune diseases treatment market studies various drugs used for treatment of autoimmune diseases along with pipeline analysis of upcoming potential drugs. Autoimmune diseases (ADs) are a family of more than 80 chronic, and often disabling, illnesses broadly characterized by immune system dysfunction leading to the loss of tolerance to self-antigens, presence of increased level of autoantibodies, inflammatory and mediatory cells and resulting chronic inflammation. Thus, drug pipeline of autoimmune diseases treatment market comprises potential drugs which are more target-specific and possess innovative properties.
For the purpose of this study, the various therapeutic types studied include chemical-based drugs and biological drugs; further, chemical-based are segmented as immunosuppressant drugs, NSAIDs, and corticosteroids. Market size estimates and forecast for these segments for the period 2020 to 2030 are provided in terms of USD Mn along with the respective CAGRs for the period 2022 to 2030, considering 2021 as the base year.
The pipeline analysis for autoimmune diseases treatment market comprises projected market sales of Phase III drugs estimated till 2022. There are more than 80 types of clinically different autoimmune diseases. Some of the common types of autoimmune diseases are Hashimoto's thyroiditis, type I diabetes, Crohn's disease, multiple sclerosis, rheumatoid arthritis, ankylosing spondylitis systemic lupus erythematosus, and psoriasis. We have estimated sales of very specific molecules based on the type (chemical-based or biological), disease prevalence, sponsor, depicted peak sales by leading market experts and other factors.
The geographic segmentation of the global autoimmune diseases treatment market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2020 to 2030 are provided in terms of USD Mn along with the respective CAGRs for the period 2022 to 2030, considering 2021 as the base year.
North America was observed as the largest market for autoimmune diseases treatment in the base year 2015 due to growing prevalence of several forms of autoimmune disorders, and presence of government initiatives such as Affordable Care Act and Patient Protection Act. According to the American Autoimmune Related Diseases Association (AARDA), autoimmune disease is one of the top 10 leading causes of death in female children and women in all age groups up to 64 years of age and AARDA also estimates that around 50 million Americans suffer from autoimmune disease. Europe is expected to be the second largest market due to rising healthcare infrastructure and penetration of new technologies. Dominance of North America and Europe in autoimmune disease market is attributed by factors like rising prevalence of autoimmune diseases, increasing investments in R&D and higher disposable income in these regions. However, factors such as developing health infrastructure, increasing awareness among people about heath care and aging population are going to fuel the rapid growth of autoimmune disease treatment market in Asia-Pacific region in the near future.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
For the purpose of this study, the various therapeutic types studied include chemical-based drugs and biological drugs; further, chemical-based are segmented as immunosuppressant drugs, NSAIDs, and corticosteroids. Market size estimates and forecast for these segments for the period 2020 to 2030 are provided in terms of USD Mn along with the respective CAGRs for the period 2022 to 2030, considering 2021 as the base year.
The pipeline analysis for autoimmune diseases treatment market comprises projected market sales of Phase III drugs estimated till 2022. There are more than 80 types of clinically different autoimmune diseases. Some of the common types of autoimmune diseases are Hashimoto's thyroiditis, type I diabetes, Crohn's disease, multiple sclerosis, rheumatoid arthritis, ankylosing spondylitis systemic lupus erythematosus, and psoriasis. We have estimated sales of very specific molecules based on the type (chemical-based or biological), disease prevalence, sponsor, depicted peak sales by leading market experts and other factors.
The geographic segmentation of the global autoimmune diseases treatment market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2020 to 2030 are provided in terms of USD Mn along with the respective CAGRs for the period 2022 to 2030, considering 2021 as the base year.
Therapeutics type Analysis
According to market experts, biologic therapy is increasingly used to treat autoimmune disorders in developed markets, but usage is still low in emerging markets. Biologic therapies have been acknowledged as effective treatments for a variety of autoimmune diseases. However, the associated costs are high due to complex manufacturing processes. In 2012, a study carried out by the National Institute for Health and Care Excellence (NICE) found that in UK biologic drugs cost twenty times as much as conventional therapy. In base year 2021, chemical based drugs accounted for the major market share but during the forecast period 2022 - 2030 biologic drugs are expected to project a significant growth. The key factors assisting the segment growth were with enhanced reimbursement policies have increased the use of biological drugs in developed markets, growing prevalence of autoimmune diseases coupled with growing public awareness, and technological advancements such as the development of novel biomarkers such as Enbrel and Humira.North America was observed as the largest market for autoimmune diseases treatment in the base year 2015 due to growing prevalence of several forms of autoimmune disorders, and presence of government initiatives such as Affordable Care Act and Patient Protection Act. According to the American Autoimmune Related Diseases Association (AARDA), autoimmune disease is one of the top 10 leading causes of death in female children and women in all age groups up to 64 years of age and AARDA also estimates that around 50 million Americans suffer from autoimmune disease. Europe is expected to be the second largest market due to rising healthcare infrastructure and penetration of new technologies. Dominance of North America and Europe in autoimmune disease market is attributed by factors like rising prevalence of autoimmune diseases, increasing investments in R&D and higher disposable income in these regions. However, factors such as developing health infrastructure, increasing awareness among people about heath care and aging population are going to fuel the rapid growth of autoimmune disease treatment market in Asia-Pacific region in the near future.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Autoimmune Diseases Treatment market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Autoimmune Diseases Treatment market and their expected impact during the forecast period.
Market Segmentation
Type of Threapeutic
- Chemical-based Drugs
- Immunosuppressant Drugs
- NSAIDs
- Corticosteroids
- Biological Drugs
- Pipeline Analysis
- Projected sales of Phase III Drugs estimated till 2022, by Most Prevalent Autoimmune Diseases (US$ Mn)
- Hashimoto's Thyroiditis
- Type I Diabetes
- Crohn's Disease
- Multiple Sclerosis
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Systemic Lupus Erythematosus
- Psoriasis
- Tabular Representation of Phase II and I Drugs
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Autoimmune Diseases Treatment market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Autoimmune Diseases Treatment market?
- Which is the largest regional market for Autoimmune Diseases Treatment market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Autoimmune Diseases Treatment market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Autoimmune Diseases Treatment market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface
2. Executive Summary
3. Autoimmune Diseases Treatment Market: Competitive Analysis
4. Autoimmune Diseases Treatment Market: Macro Analysis & Market Dynamics
5. Autoimmune Diseases Treatment Market: By Type of Threapeutic, 2020-2030, USD (Million)
6. North America Autoimmune Diseases Treatment Market, 2020-2030, USD (Million)
7. UK and European Union Autoimmune Diseases Treatment Market, 2020-2030, USD (Million)
8. Asia Pacific Autoimmune Diseases Treatment Market, 2020-2030, USD (Million)
9. Latin America Autoimmune Diseases Treatment Market, 2020-2030, USD (Million)
10. Middle East and Africa Autoimmune Diseases Treatment Market, 2020-2030, USD (Million)
11. Company Profile
List of Figures
List of Tables
Companies Mentioned
- Genentech Inc.
- Bayer AG
- Merck & Co.
- Amgen Inc.
- Johnson & Johnson Limited
- Abbott Laboratories
- Eli Lilly and Company
- GlaxoSmithKline Plc
- F. Hoffmann-La Roche AG
- Bristol Myers Squibb Company.
